# Liposoluble vitamins in patients receiving long-term octreotide treatment

Published: 12-01-2009 Last updated: 05-05-2024

To determine the frequency and severity of liposoluble vitamin malabsorption side effects of long term octreotide treatment and/or small bowel resection

**Ethical review** Approved WMO

**Status** Pending

**Health condition type** Vitamin related disorders **Study type** Observational non invasive

## **Summary**

## ID

NL-OMON32903

#### Source

ToetsingOnline

## **Brief title**

Liposoluble vitamins during octreotide treatment

## **Condition**

Vitamin related disorders

## **Synonym**

liposoluble vitamin deficiency, shortage of liposoluble vitamins

## Research involving

Human

## **Sponsors and support**

**Primary sponsor:** Universitair Medisch Centrum Groningen

Source(s) of monetary or material Support: Ministerie van OC&W

## Intervention

**Keyword:** acromegaly, carcinoid tumor, liposoluble vitamins, octreotide

1 - Liposoluble vitamins in patients receiving long-term octreotide treatment 4-05-2025

### **Outcome measures**

## **Primary outcome**

Patients will be investigated for vitamin-status by measuring liposoluble vitamins, relevant lipid components and relevant biochemical investigations to measure effects of possible vitamin deficiency, including calciumlevels, PTH and coagulation in blood

## **Secondary outcome**

-

# **Study description**

## **Background summary**

Long-term octreotide therapy is an important medical treatment to control symptoms of hypersecretion of biological active amines and peptides in a number of diseases, such as acromegaly or carcinoid tumours. Side effects of octreotide treatment are usually acceptable and often passing. Octreotdide is registered for clinical use since 1989, while the now commonly used long-acting form became available in 1997.

There is some evidence pointing towards a risk liposoluble vitamin deficiency in patients receiving long-term octreotide treatment. This is becoming clear only recently as there are now patients using this drug since it became available. Groups especially using octreotide are acormegaly patients and patients with carcinoid, who have as additional reason for vitamin deficiency the fact that often a part of the small bowel is resected. However, vitamin status is not routinely assessed in these patients, even though vitamin deficiency can seriously affect quality of life.

## Study objective

To determine the frequency and severity of liposoluble vitamin malabsorption side effects of long term octreotide treatment and/or small bowel resection

## Study design

This is a cross-sectional explorative cohort study in patients receiving

2 - Liposoluble vitamins in patients receiving long-term octreotide treatment 4-05-2025

long-term octreotide treatment for acromegaly or a carcinoid tumour. Patients are eligible when they have used octreotide for at least 18 months. Patients must be 18 years or older and must be willing to give written informed consent This investigation will be done by blood analysis at one time point

## Study burden and risks

The blood analysis will be performed during routine outpatient visits, when regular blood samples are drawn. No serious adverse events are linked to the described study procedures. With this study we hope to get insight into the frequency and severity of deficiency of liposoluble vitamins in patients receiving long-term octreotide therapy. This will contribute to the early recognition and suppletion of (sub)clinical deficiencies thus improving patient\*s health.

## **Contacts**

#### **Public**

Universitair Medisch Centrum Groningen

Hanzeplein 1 9713 GZ Groningen Nederland

**Scientific** 

Universitair Medisch Centrum Groningen

Hanzeplein 1 9713 GZ Groningen Nederland

# **Trial sites**

## **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years)

3 - Liposoluble vitamins in patients receiving long-term octreotide treatment 4-05-2025

Elderly (65 years and older)

## **Inclusion criteria**

octreotide-treatment longer than 18 months

## **Exclusion criteria**

\_

# Study design

# **Design**

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

## Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-12-2008

Enrollment: 80

Type: Anticipated

## **Ethics review**

Approved WMO

Application type: First submission

Review commission: METC Universitair Medisch Centrum Groningen (Groningen)

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

Register ID

CCMO NL25367.042.08